Display options
Cite
Onishi Y, Koshiyama H, Imaoka T, et al. Safety of exenatide once weekly for 52 weeks in Japanese patients with type 2 diabetes mellitus. J Diabetes Investig. 2012;4(2):182-9doi: 10.1111/jdi.12000.
Onishi, Y., Koshiyama, H., Imaoka, T., Haber, H., Scism-Bacon, J., & Boardman, M. K. (2013). Safety of exenatide once weekly for 52 weeks in Japanese patients with type 2 diabetes mellitus. Journal of diabetes investigation, 4(2), 182-9. https://doi.org/10.1111/jdi.12000
Onishi, Yukiko, et al. "Safety of exenatide once weekly for 52 weeks in Japanese patients with type 2 diabetes mellitus." Journal of diabetes investigation vol. 4,2 (2013): 182-9. doi: https://doi.org/10.1111/jdi.12000
Onishi Y, Koshiyama H, Imaoka T, Haber H, Scism-Bacon J, Boardman MK. Safety of exenatide once weekly for 52 weeks in Japanese patients with type 2 diabetes mellitus. J Diabetes Investig. 2013 Mar 18;4(2):182-9. doi: 10.1111/jdi.12000. Epub 2012 Oct 22. PMID: 24843650; PMCID: PMC4019273.
Copy Download .nbib Format: NLM
Share it on

J Diabetes Investig. 2013 Mar 18;4(2):182-9. doi: 10.1111/jdi.12000. Epub 2012 Oct 22.

Safety of exenatide once weekly for 52 weeks in Japanese patients with type 2 diabetes mellitus.

Journal of diabetes investigation

Yukiko Onishi, Hiroyuki Koshiyama, Takeshi Imaoka, Harry Haber, Jamie Scism-Bacon, Marilyn K Boardman

Affiliations

  1. The Institute for Adult Diseases Asahi Life Foundation Tokyo Japan.
  2. Center for Diabetes and Endocrinology Medical Research Institute Kitano Hospital Osaka Japan.
  3. Diabetes Products Eli Lilly Japan Kobe.
  4. PharmaNet/i3, an inVentiv Health Company Ann Arbor MI USA.
  5. PharmaNet/i3, an inVentiv Health Company Indianapolis IN USA.
  6. Lilly Diabetes Eli Lilly and Company Indianapolis IN USA.

PMID: 24843650 PMCID: PMC4019273 DOI: 10.1111/jdi.12000

Abstract

AIMS/INTRODUCTION: An initial 26-week, randomized, open-label study compared the efficacy and safety of exenatide 10 mcg twice daily with exenatide 2 mg once weekly in Asian patients with type 2 diabetes who experienced inadequate glycemic control with oral antidiabetes medications. The aim of this study was to evaluate the safety of exenatide once weekly in Japanese patients, a subset of the initial patient population, who continued into this extension study for an additional 26 weeks of therapy on exenatide once weekly, followed by 10 weeks without exenatide once weekly.

MATERIALS AND METHODS: Japanese patients initially assigned to exenatide twice daily (n = 62) switched to exenatide once weekly for the extended 26 weeks, and patients initially assigned to exenatide once weekly (n = 74) continued on this regimen for the remainder of the study (total treatment of 52 weeks).

RESULTS: A total of 68% of patients reported one or more treatment-emergent adverse events during the extension period; the most common of these were nasopharyngitis (14%) and vomiting (6%). No major hypoglycemic episodes were reported. Improvements in glycated hemoglobin, fasting plasma glucose and postprandial glucose were maintained over 52 weeks of treatment. At week 52, bodyweight remained reduced from baseline.

CONCLUSIONS: Exenatide once weekly added to oral antidiabetes medication was well tolerated in Japanese patients with type 2 diabetes, and was associated with glycemic control and weight loss through to 52 weeks, supporting the use of exenatide once weekly as an adjunctive treatment for type 2 diabetes in this patient population. The initial 26-week portion of this trial was registered with ClinicalTrials.gov (no. NCT00917267).

Keywords: Blood glucose; Exenatide; Japanese

References

  1. Diabetes Care. 2004 May;27(5):1047-53 - PubMed
  2. Diabetes Care. 2005 May;28(5):1083-91 - PubMed
  3. Horm Metab Res. 1996 Sep;28(9):522-6 - PubMed
  4. Endocr J. 2010;57(6):499-507 - PubMed
  5. Lancet. 2008 Oct 4;372(9645):1240-50 - PubMed
  6. Diabetes Metab Res Rev. 2009 Nov;25(8):705-16 - PubMed
  7. Diabetes Care. 2004 Nov;27(11):2628-35 - PubMed
  8. Diabetes Care. 2010 Jun;33(6):1255-61 - PubMed
  9. J Diabetes Investig. 2011 Jun 5;2(3):210-7 - PubMed
  10. J Clin Endocrinol Metab. 2011 May;96(5):1301-10 - PubMed
  11. Diabetes Care. 2012 Apr;35(4):683-9 - PubMed
  12. Diabetes Obes Metab. 2012 Jun;14(6):546-54 - PubMed
  13. Diabetes Res Clin Pract. 2006 Aug;73(2):198-204 - PubMed
  14. Diabetes Care. 2005 May;28(5):1092-100 - PubMed
  15. Diabetes Metab Syndr Obes. 2012;5:29-41 - PubMed

Publication Types